Dystrogen.com Website Review

is a clinical stage regenerative medicine company focusing on rare diseases. The company is currently testing DEC therapy for Duchenne Professor Siemionow’s research focused on creating cell hybrids, referred to as chimeras. This has lead to the development of Dystrophin Expressing Chimeric (DEC) cell therapy. DECs work by combining a malfunctioning cell of the Duchenne patient with a working cell from a healthy donor. This offers a unique advantage and allows the patients’ body and immune system to accept the new cell without rejection. The new cell is composed of both donor and recipient structures and interacts with its surroundings like a normal cell. In such a way we have created dystrophin producing cells that can engraft inside the patient's muscles and increase their dystrophin levels. Increased dystrophin levels have been shown to correlate with improved functional outcomes. This technology was developed at the University DYSTROGEN THERA*EUTICS is a life science company focused on rare diseases. The company has developed dystrophin expressing chimeric (DEC) therapy. DEC therapy is a candidate for the treatment of Duchenne muscular dystrophy. The company is currently preparing to improved muscle function at 90 days post intramuscular transplant.. MARIA SIEMIONOW, MD, PHD, FOUNDER AND CHIEF SCIENTIFIC OFFICER. Dr. Siemionow spent decades investigating the effect of chimeric cells – made by fusing donor and recipient bone marrow stem cells – on the immune system’s natural attack response to foreign tissues and donor organs. If the immune system leaves these chimeric cells alone as part “self,” implanted donor tissue may be spared a full-blown rejection response. Dr. Siemionow is president of the American Society for Reconstructive Transplantation and past president of the International Hand and Composite Tissue Allotransplantation Society and the American Society for Peripheral Nerve.  She is a member of the academic-industry team known as the Warrior Restoration